Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal NK Cells in High-grade Gliomas
NCT06687681Phase 2Recruiting
- Sponsor
- Marzieh Ebrahimi
- Start
- Nov 2024
- Primary completion
- Nov 2025
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in glioma (2 arms), sponsored by Marzieh Ebrahimi. Primary endpoint: Tumor Response after infusion of intrathecal NK cells at 12 months. Started Nov 2024; status: recruiting.
02
Conditions
glioma
Beyond the preview
Go deeper on NCT06687681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06687681.